Insider Transactions in Q2 2023 at Spring Works Therapeutics, Inc. (SWTX)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2023
|
L. Mary Smith Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,720
+2.56%
|
-
|
|
Jun 30
2023
|
James Cassidy Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,720
+9.75%
|
-
|
|
Jun 20
2023
|
Julie Hambleton Director |
SELL
Open market or private sale
|
Direct |
2,400
-25.35%
|
$62,400
$26.92 P/Share
|
|
May 24
2023
|
Jeffrey Lawrence Schwartz Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,648
+30.54%
|
-
|
|
May 24
2023
|
Carlos Alban Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,648
+24.02%
|
-
|
|
May 24
2023
|
Alan Fuhrman Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,648
+30.54%
|
-
|
|
May 24
2023
|
Julie Hambleton Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,648
+32.93%
|
-
|
|
May 24
2023
|
Freda C Lewis Hall Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,648
+30.54%
|
-
|
|
May 24
2023
|
Daniel Lynch Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,648
+1.52%
|
-
|
|
Apr 03
2023
|
Bhavesh Ashar Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,375
-3.05%
|
$34,375
$25.25 P/Share
|